title: Immunophenotype and DNA cell content in multiple myeloma.
abstract: In this paper three different areas of the biology of multiple myeloma (MM) are reviewed: (1) the immunophenotypic characteristics of plasma cells (PC), (2) the changes in the immunoregulatory cells, and (3) the cell DNA content of PC. Myelomatous PC display a heterogeneous phenotype not only between different patients but also within each patient consistent with the fact that the neoplastic clone is able to undergo a certain degree of differentiation. In addition, PC generally lack surface B cell associated antigens and infrequently show reactivity for non-lineage restricted markers. The B-B4 and CD38 are the two best markers for identifying PC which are crucial for the correct assessment of other antigens by multiple staining procedures. Moreover, some of the antigens present in PC such as CD56, CD20, CD10, CD28 and SIg may have prognostic implications. Whether or not normal PC are phenotypically different from myelomatous PC remains controversial although some antigenic combinations such as CD19-/CD56++ could probably help to identify the malignant nature of PC. Both T and NK cells are markedly altered in MM patients probably reflecting a host-tumour immunological interaction. The reduction in CD4 cells correlates both with advanced clinical stage and poor survival. As far as NK cells are concerned, there is an overall increase in peripheral blood and BM in MM patients but the changes observed are heterogeneous, reflecting the existence of different NK cell subsets. This fact could explain the contradictory results observed in the literature. Accumulating evidence exists that the measurement of cell DNA content by flow cytometry is a useful parameter in the clinical evaluation of MM patients. Between 50 and 70% of MM patients display DNA aneuploidy with the majority of them hyperdiploid. Upon comparing hyperdiploid with diploid patients, the former usually display a better prognosis. The possibility of analysing the cell cycle distribution by using a PI/CD38 double staining technique may be an alternative to other more laborious methods of assessing the PC labelling index. In our experience, patients with > 3% S phase PC have an adverse prognosis and this parameter was the most important independent prognostic criteria for predicting survival.
authors.affiliation: Department of Haematology, University of Salamanea, Spain.
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: R
authors.initials: R
authors.lastname: Garcia-Sanz
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: A
authors.initials: A
authors.lastname: Orfao
mesh_terms: D002453:Cell Cycle / Q000502:physiology; D004273:DNA, Neoplasm / Q000032:analysis*; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology; D009101:Multiple Myeloma / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D010950:Plasma Cells / Q000276:immunology*; D011003:Ploidies; D016176:T-Lymphocyte Subsets / Q000276:immunology
chemical_list: D004273:DNA, Neoplasm